新闻BenzingaKodiak Sciences Says Phase 3 DAYBREAK Study Met Primary Endpoints With Zenkuda (Tarcocimab Tedromer) And Tabirafusp-ted (KSI-501) Showing Non-inferiority In Vision Gains For Wet Age-related Macular Degeneration Vs. Aflibercept At Year One Kodiak Sciences Says Phase 3 DAYBREAK Study Met Primary Endpoints With Zenkuda (Tarcocimab Tedromer) And Tabirafusp-ted (KSI-501) Showing Non-inferiority In Vision Gains For Wet Age-related Macular Degeneration Vs. Aflibercept At Year One Benzinga 2026.09.28 10:34 (GMT+0) 在Benzinga上打开 其他新闻 ARK告知SEC不打算推进两只加密ETF 币安Alpha上线STBL,开放1675枚空投领取 以太坊联创Vitalik批评奈飞FTX题材新剧对CZ的刻画涉嫌种族歧视 今日股票:美光会跌到多低? ANT、NVDA、PANW 等:本周投资者热议不止的 5 只股票 Benzinga的“股票耳语”指数:投资者秘密关注但尚未公开谈论的五只股票